Osei-Wusuansa, Maria, Mohammed, Nura, Makanjuola, Damilola, Habas, Khaled, Sener, Sila Ozlem, Assi, Khaled H., Nasim, Rateep, Nawaz, Sadaf, Gopalan, Rajendran C., Wright, Colin W., and others. (2024) Therapeutic Resolution of Pulmonary Arterial Hypertension (PAH) Using Natural Products. Targets, 2 (4). pp. 428-445. ISSN 2813-3137. (doi:10.3390/targets2040024) (KAR id:108367)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/1MB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.3390/targets2040024 |
Abstract
Pulmonary arterial hypertension (PAH) is a progressive and rare condition characterised by the occlusion of pulmonary arterioles, with clinical manifestations resulting from the cross-sectional area reduction of the small pulmonary arteries. The disease is driven by a combination of factors including vasoconstriction, thrombosis, inflammation, proliferation, and the obstructive remodelling of the pulmonary artery walls. Heterozygous mutations in the type II bone morphogenetic protein receptor (BMPR2) underlie the majority of the inherited and familial forms of PAH. Current evidence indicates that in PAH, the BMPR2-mediated-signalling is diminished and the TGFβ signalling is heightened. Even when managed with current therapeutic approaches, the disease eventually results in increased pulmonary vascular resistance, right heart failure, and premature death. Natural products act as vascular disease treatment agents and have been used in clinical practice following compelling clinical trials. The rationale for the selection of natural compounds derives from their multi-targeted approach and synergistic effects. Although novel medicines licenced by the FDA (USA) between 1981 and 2010, constitute approximately 34% natural products or derivatives of natural products, their potentials for the treatment of PAH are not fully explored. The objective of this review is to emphasise the significance of natural products in the therapeutic resolution of PAH.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.3390/targets2040024 |
Uncontrolled keywords: | bone morphogenetic protein, pulmonary circulation, natural products, pulmonary arterial hypertension, transforming growth factor-β |
Subjects: |
Q Science Q Science > QH Natural history |
Divisions: | Divisions > Division of Natural Sciences > Biosciences |
Funders: |
Royal Society (https://ror.org/03wnrjx87)
Commonwealth Scholarship Commission (https://ror.org/051x4wh35) University of Bradford (https://ror.org/00vs8d940) |
SWORD Depositor: | JISC Publications Router |
Depositing User: | JISC Publications Router |
Date Deposited: | 19 Feb 2025 16:38 UTC |
Last Modified: | 24 Feb 2025 12:28 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/108367 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):